Trials / Completed
CompletedNCT03809013
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with HER2 overexpressing locally advanced or metastatic urothelial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC48-ADC | 2.0mg/kg IV every 2 weeks |
Timeline
- Start date
- 2019-01-07
- Primary completion
- 2021-03-04
- Completion
- 2023-06-05
- First posted
- 2019-01-18
- Last updated
- 2023-11-27
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03809013. Inclusion in this directory is not an endorsement.